港股異動丨勵晶太平洋(0575.HK)大漲超30% 今年底前完成Fortacin的第二階段驗證研究
格隆匯6月19日丨勵晶太平洋(0575.HK)大漲超30%,盤中漲幅一度達到54%,收報0.095港元,總市值1.75億港元。勵晶太平洋昨日公佈,集團就有關其Fortacin™之第二階段驗證研究向美國食品及藥品監督管理局申請批准一事進展穩定。集團將按照計劃於2020年底前完成Fortacin™的第二階段驗證研究。此外,Fortacin™的地位由處方藥轉為非處方藥的申請工作也進展順利。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.